ArticleJHEP reports : innovation in hepatology2025
Elevated FBXO45 promotes TFG ubiquitination and drives lung metastasis of hepatocellular carcinoma.
Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Esculentoside A suppresses the malignant progression of hepatocellular carcinoma by promoting RORB.Cell division · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Elevated F-box/SPRY domain protein 1 (FBXO45) expression is associated with human hepatocellular carcinoma (HCC). While TP53 mutations represent a common genetic alteration in HCC, the potential regulatory interplay between TP53 and FBXO45 in modulating HCC progression remains unclear. Methods: We analyzed the relationship between TP53 and FBXO45 in patients with HCC. A series of assays were also performed to explore the effect of FBXO45 on invasion and metastasis in TP53-mutated HCC cell lines and mouse models. These experimental findings were further validated in clinical samples. Results: FBXO45 expression was upregulated in 78.3% (83/106) of patients with HCC with TP53 mutation, marking an aggressive subtype. Overexpression of FBXO45 significantly enhanced HCC cell migration and invasion capacity ( Conclusions: Our results provide new mechanistic insight into the role of FBXO45 in driving HCC invasion and metastasis. Therefore, targeting the TP53-FBXO45-TFG-ATF2-NF-κB axis represents a promising therapeutic approach for treating aggressive HCC with TP53 mutations. Impact and implications: This study highlights that FBXO45 is highly expressed in patients with HCC with TP53 mutations. FBXO45 promotes HCC lung metastasis by activating the TFG-ATF2-NF-κB-epithelial-mesenchymal transition signaling axis. In addition, we found that targeting the TP53-FBXO45-TFG-ATF2-NF-κB axis could be a novel approach for the treatment of metastatic HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.